---
title: "Carisma Therapeutics, Inc. (CARM.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/CARM.US.md"
symbol: "CARM.US"
name: "Carisma Therapeutics, Inc."
industry: "Biotechnology"
---

# Carisma Therapeutics, Inc. (CARM.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.carismatx.com](https://www.carismatx.com) |

## Company Profile

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:13.000Z

**Overall: B (0.39)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 50 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 159.68% |  |
| Net Profit YoY | 112.61% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -2.12 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1.84M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 52.63M |  |


**Multi Score**: B

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -134.11% | E |
| Profit Margin | 15.28% | A |
| Gross Margin | 99.56% | A |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 159.68% | A |
| Net Profit YoY | 112.61% | A |
| Total Assets YoY | -84.42% | E |
| Net Assets YoY | 92.21% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 654.46% | C |
| OCF YoY | 159.68% | A |

#### Operating Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 2.17 | A |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 113.23% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Carisma Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-134.11%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "15.28%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "99.56%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "159.68%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "112.61%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-84.42%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "92.21%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "654.46%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "159.68%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "A",
      "indicators": [
        {
          "name": "Turnover",
          "value": "2.17",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "113.23%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 0.23 | 2/604 | 0.27 | 0.23 | 0.21 |
| PB | -2.12 | 496/604 | - | - | - |
| PS (TTM) | 0.03 | 1/604 | 0.91 | 0.44 | 0.04 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/CARM.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/CARM.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/CARM.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.